On the public citation graph

The BATTLE Trial: Personalizing Therapy for Lung Cancer

https://doi.org/10.1158/2159-8274.cd-10-0010
0 signed · 899 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.23030openalex-snapshot
Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas
inferredcites →https://doi.org/10.1002/cncr.23282openalex-snapshot
Epidermal growth factor receptor immunohistochemistry
inferredcites →https://doi.org/10.1016/j.ccr.2009.11.022openalex-snapshot
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
inferredcites →https://doi.org/10.1016/s0140-6736(08)61758-4openalex-snapshot
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
inferredcites →https://doi.org/10.1056/nejmoa040938openalex-snapshot
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
inferredcites →https://doi.org/10.1056/nejmoa050736openalex-snapshot
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
inferredcites →https://doi.org/10.1056/nejmoa050753openalex-snapshot
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa061884openalex-snapshot
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa065411openalex-snapshot
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa0810699openalex-snapshot
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
inferredcites →https://doi.org/10.1056/nejmoa0904554openalex-snapshot
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
inferredcites →https://doi.org/10.1056/nejmra0802714openalex-snapshot
Lung Cancer
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1093/jnci/dji112openalex-snapshot
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1126/science.1099314openalex-snapshot
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
inferredcites →https://doi.org/10.1158/1940-6207.capr-10-0376openalex-snapshot
Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models
inferredcites →https://doi.org/10.1177/1740774508091815openalex-snapshot
Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine
inferredcites →https://doi.org/10.1177/1740774510373120openalex-snapshot
Bayesian adaptive randomization designs for targeted agent development
inferredcites →https://doi.org/10.1200/jco.2000.18.12.2354openalex-snapshot
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
inferredcites →https://doi.org/10.1200/jco.2005.01.9521openalex-snapshot
Bexarotene and Erlotinib for Aerodigestive Tract Cancer
inferredcites →https://doi.org/10.1200/jco.2005.14.373openalex-snapshot
Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2006.08.2099openalex-snapshot
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2007.13.0344openalex-snapshot
Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials
inferredcites →https://doi.org/10.1200/jco.2007.15.0375openalex-snapshot
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2008.18.6015openalex-snapshot
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.8014openalex-snapshot
A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501
inferredcites →https://doi.org/10.1200/jco.2009.21.9766openalex-snapshot
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2009.22.6993openalex-snapshot
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
inferredcites →https://doi.org/10.1200/jco.2009.24.3030openalex-snapshot
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
inferredcites →https://doi.org/10.3322/caac.20073openalex-snapshot
Cancer Statistics, 2010

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3397464openalex-extracted
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.49998openalex-snapshot
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.19972openalex-snapshot
Biomarker Testing in Advanced Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2016.2129openalex-snapshot
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
inferred← citeshttps://doi.org/10.1002/1878-0261.13605openalex-snapshot
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
inferred← citeshttps://doi.org/10.1002/9781118337929.ch10openalex-snapshot
Controversies in Adjuvant Chemotherapy
inferred← citeshttps://doi.org/10.1002/9781118445112.stat04981.pub2openalex-snapshot
Sequential Analysis – Further Developments Updated with a Focus on Biomedical, Economic, and Engineering Applications
inferred← citeshttps://doi.org/10.1002/9781118445112.stat07845openalex-snapshot
Ethics of Outcome Adaptive Randomization
inferred← citeshttps://doi.org/10.1002/9781118468678.ch1openalex-snapshot
Toward Personalized Therapy for Cancer
inferred← citeshttps://doi.org/10.1002/9781118468678.ch23openalex-snapshot
Targeted Therapy in Solid Tumors: Lung Cancer
inferred← citeshttps://doi.org/10.1002/9781118468791.ch31openalex-snapshot
Novel Clinical Trial Designs for Metastatic Lung Cancer
inferred← citeshttps://doi.org/10.1002/9781118468791.ch32openalex-snapshot
Novel Statistical Models for NSCLC Clinical Trials
inferred← citeshttps://doi.org/10.1002/9781118468791.ch33openalex-snapshot
Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy
inferred← citeshttps://doi.org/10.1002/9781118468791.ch34openalex-snapshot
Anti‐Angiogenic Agents in Metastatic NSCLC
inferred← citeshttps://doi.org/10.1002/9781118628003.ch26openalex-snapshot
Advances in the Use of Retinoids in Cancer Therapy and Prevention
inferred← citeshttps://doi.org/10.1002/9781118874905.ch18openalex-snapshot
Therapeutic Exploratory Trials
inferred← citeshttps://doi.org/10.1002/9781118874905.refsopenalex-snapshot
Cumulative References
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm007openalex-snapshot
Cancer Genomics and Evolution
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm007.pub2openalex-snapshot
Cancer Genomics and Evolution
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm020openalex-snapshot
Statistical Innovations in Cancer Research
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm020.pub2openalex-snapshot
Statistical Innovations in Cancer Research
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm021openalex-snapshot
Biomarker‐Based Clinical Trial Design in the Era of Genomic Medicine
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm021.pub2openalex-snapshot
Biomarker Based Clinical Trial Design in the Era of Genomic Medicine
inferred← citeshttps://doi.org/10.1002/9781119524687.refsopenalex-snapshot
References
inferred← citeshttps://doi.org/10.1002/9781119711414.ch18openalex-snapshot
Gums‐Based Bionanostructures for Medical Applications
inferred← citeshttps://doi.org/10.1002/9783527677252.ch07openalex-snapshot
Identifying Actionable Targets in Cancer Patients
inferred← citeshttps://doi.org/10.1002/asmb.2249openalex-snapshot
Combining Bayesian experimental designs and frequentist data analyses: motivations and examples
inferred← citeshttps://doi.org/10.1002/bimj.202200301openalex-snapshot
Response‐adaptive randomization for multiarm clinical trials using context‐dependent information measures
inferred← citeshttps://doi.org/10.1002/cam4.1454openalex-snapshot
The importance of greater speed in drug development for advanced malignancies
inferred← citeshttps://doi.org/10.1002/cncr.28304openalex-snapshot
Integration of cancer genomics with treatment selection
inferred← citeshttps://doi.org/10.1002/cncr.28966openalex-snapshot
Attitudes toward molecular testing for personalized cancer therapy
inferred← citeshttps://doi.org/10.1002/cncr.29098openalex-snapshot
Small cell lung cancer: Where do we go from here?
inferred← citeshttps://doi.org/10.1002/cncr.34757openalex-snapshot
Targeted therapy for lung cancer: Beyond EGFR and ALK
inferred← citeshttps://doi.org/10.1002/cncy.21960openalex-snapshot
SOX10/keratin dual‐color immunohistochemistry: An effective first‐line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens
inferred← citeshttps://doi.org/10.1002/cncy.22234openalex-snapshot
Diagnostic efficacy and molecular testing by combined fine‐needle aspiration and core needle biopsy in patients with a lung nodule
inferred← citeshttps://doi.org/10.1002/cpt.1947openalex-snapshot
Strategies for Testing Intervention Matching Schemes in Cancer
inferred← citeshttps://doi.org/10.1002/cpt.446openalex-snapshot
Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker
inferred← citeshttps://doi.org/10.1002/cpt.59openalex-snapshot
From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
inferred← citeshttps://doi.org/10.1002/cpt.814openalex-snapshot
Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials
inferred← citeshttps://doi.org/10.1002/cpt.88openalex-snapshot
Innovative Clinical Trials: The LUNG‐MAP Study
inferred← citeshttps://doi.org/10.1002/ijc.27817openalex-snapshot
Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial
inferred← citeshttps://doi.org/10.1002/ijc.28882openalex-snapshot
Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers
inferred← citeshttps://doi.org/10.1002/ijc.28940openalex-snapshot
Personalised cancer medicine
inferred← citeshttps://doi.org/10.1002/ijc.33053openalex-snapshot
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1002/iub.369openalex-snapshot
Conquering cancer through discovery research
inferred← citeshttps://doi.org/10.1002/jcb.26847openalex-snapshot
Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells
inferred← citeshttps://doi.org/10.1002/nav.22028openalex-snapshot
Technical note—Knowledge gradient for selection with covariates: Consistency and computation
inferred← citeshttps://doi.org/10.1002/path.4275openalex-snapshot
The evolving genomic classification of lung cancer
inferred← citeshttps://doi.org/10.1002/pbc.24018openalex-snapshot
Personalized cancer care: Opportunities and challenges in pediatric neuro‐oncology
inferred← citeshttps://doi.org/10.1002/pro6.1191openalex-snapshot
Application of radiomics in lung immuno‐oncology
inferred← citeshttps://doi.org/10.1002/sam.11681openalex-snapshot
Randomized multiarm bandits: An improved adaptive data collection method
inferred← citeshttps://doi.org/10.1002/sim.10047openalex-snapshot
Doubly adaptive biased coin design to improve Bayesian clinical trials with time‐to‐event endpoints
inferred← citeshttps://doi.org/10.1002/sim.5404openalex-snapshot
Bayesian clinical trials in action
inferred← citeshttps://doi.org/10.1002/sim.5573openalex-snapshot
Designing a series of decision‐theoretic phase II trials in a small population
inferred← citeshttps://doi.org/10.1002/sim.6086openalex-snapshot
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials
inferred← citeshttps://doi.org/10.1002/sim.7091openalex-snapshot
Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials
inferred← citeshttps://doi.org/10.1002/sim.7422openalex-snapshot
Inference for multimarker adaptive enrichment trials
inferred← citeshttps://doi.org/10.1002/sim.7946openalex-snapshot
Adaptive enrichment designs for confirmatory trials
inferred← citeshttps://doi.org/10.1002/sim.8160openalex-snapshot
Implementing unequal randomization in clinical trials with heterogeneous treatment costs
inferred← citeshttps://doi.org/10.1002/sim.8946openalex-snapshot
Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS)
inferred← citeshttps://doi.org/10.1002/sim.9132openalex-snapshot
Lasso estimation of hierarchical interactions for analyzing heterogeneity of treatment effect
inferred← citeshttps://doi.org/10.1002/sim.9605openalex-snapshot
Point estimation for adaptive trial designs I: A methodological review
inferred← citeshttps://doi.org/10.1002/sim.9734openalex-snapshot
Point estimation for adaptive trial designs II : Practical considerations and guidance
inferred← citeshttps://doi.org/10.1007/128_2012_338openalex-snapshot
Personalizing Lung Cancer Prevention Through a Reverse Migration Strategy
inferred← citeshttps://doi.org/10.1007/978-0-85729-910-9_25openalex-snapshot
Trial Design: Should Randomized Phase III Trials in Gynecological Cancers Be Abandoned?
inferred← citeshttps://doi.org/10.1007/978-1-4419-0787-5_14openalex-snapshot
Molecular Pathology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4471-4679-7_14openalex-snapshot
Trial Design: Overview of Study Designs (Phase I, II, III, IV, Factorial Design)
inferred← citeshttps://doi.org/10.1007/978-1-4939-0727-4_12openalex-snapshot
Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice
inferred← citeshttps://doi.org/10.1007/978-1-4939-1176-9_13openalex-snapshot
Phase I–II Targeted Treatments
inferred← citeshttps://doi.org/10.1007/978-3-030-16391-4_3openalex-snapshot
The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers
inferred← citeshttps://doi.org/10.1007/978-3-030-23637-3_4openalex-snapshot
Precision Cancer Medicine and Clinical Trial Design
inferred← citeshttps://doi.org/10.1007/978-3-030-31503-0_5openalex-snapshot
Statistical Considerations in the Development of Companion Diagnostic Device
inferred← citeshttps://doi.org/10.1007/978-3-030-31503-0_8openalex-snapshot
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
inferred← citeshttps://doi.org/10.1007/978-3-030-42196-0_17openalex-snapshot
Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_27openalex-snapshot
Tumor Board and Molecular Tumor Board
inferred← citeshttps://doi.org/10.1007/978-3-030-83047-2_19openalex-snapshot
Artificial Intelligence in Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-030-84172-0_59openalex-snapshot
Tubes and Biopsies
inferred← citeshttps://doi.org/10.1007/978-3-031-50690-1_4openalex-snapshot
Policy Learning for Individualized Treatment Regimes on Infinite Time Horizon
inferred← citeshttps://doi.org/10.1007/978-3-032-19175-5_11openalex-snapshot
Statistics of Randomized Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-032-19175-5_6openalex-snapshot
Adaptive Randomized Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-15811-2_2openalex-snapshot
Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-15811-2_4openalex-snapshot
Mutational Similarities Across Cancers: Implications for Research, Diagnostics, and Personalized Therapy Design
inferred← citeshttps://doi.org/10.1007/978-3-319-19518-6_15openalex-snapshot
Biomarker-Driven Adaptive Design
inferred← citeshttps://doi.org/10.1007/978-3-319-22189-2_8openalex-snapshot
Designs for Evaluating Precision Medicine Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-39053-6_1openalex-snapshot
Overview of Oncology Drug Development
inferred← citeshttps://doi.org/10.1007/978-3-319-40793-7_6openalex-snapshot
Incorporating Clinical Biomarkers into Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-42252-7_2openalex-snapshot
Biomarkers in Clinical Trials for Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-319-45345-3_11openalex-snapshot
Harnessing the Power of the Human Immune System via Multi-omic Immune Profiling in Stroke Treatment and Recovery
inferred← citeshttps://doi.org/10.1007/978-3-319-52636-2_107openalex-snapshot
Platform Trial Designs
inferred← citeshttps://doi.org/10.1007/978-3-319-52636-2_271openalex-snapshot
Inferential Frameworks for Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-52677-5_107-1openalex-snapshot
Platform Trial Designs
inferred← citeshttps://doi.org/10.1007/978-3-319-52677-5_271-1openalex-snapshot
Inferential Frameworks for Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-3-319-59856-7_1openalex-snapshot
Building Translational Research Infrastructure and Access to Expertise for Biomarker Discovery in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-62941-4_21openalex-snapshot
Liquid Biopsies
inferred← citeshttps://doi.org/10.1007/978-3-319-67386-8_11openalex-snapshot
A Novel Framework for Bayesian Response-Adaptive Randomization
inferred← citeshttps://doi.org/10.1007/978-3-319-71324-3_10openalex-snapshot
How to Design Phase I Trials in Oncology
inferred← citeshttps://doi.org/10.1007/978-3-319-71324-3_11openalex-snapshot
The Many Different Designs of Phase II Trials in Oncology
inferred← citeshttps://doi.org/10.1007/978-3-319-72661-8_2openalex-snapshot
Pathology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-73506-1_14openalex-snapshot
Novel Trial Design in Sepsis
inferred← citeshttps://doi.org/10.1007/978-3-319-95228-4_10openalex-snapshot
Personalized Cancer Treatment and Patient Stratification Using Massive Parallel Sequencing (MPS) and Other OMICs Data
inferred← citeshttps://doi.org/10.1007/978-3-319-95228-4_2openalex-snapshot
Introduction to Clinical Trials, Clinical Trial Designs, and Statistical Terminology Used for Predictive Biomarker Research and Validation
inferred← citeshttps://doi.org/10.1007/978-3-319-95228-4_53openalex-snapshot
Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities – Lessons Learnt
inferred← citeshttps://doi.org/10.1007/978-3-319-96830-8_13openalex-snapshot
Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice
inferred← citeshttps://doi.org/10.1007/978-3-319-98944-0_12openalex-snapshot
Molecular Profiling in Pancreatic Ductal Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_389-1openalex-snapshot
Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren
inferred← citeshttps://doi.org/10.1007/978-981-10-7820-0_2openalex-snapshot
Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-981-15-5999-0_3openalex-snapshot
Diverse Cancer Therapeutic Interactions: Complexities in Cancer Management
inferred← citeshttps://doi.org/10.1007/978-981-19-0197-3_15openalex-snapshot
Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-981-95-6845-1_6openalex-snapshot
Precision Cancer Medicine in Clinical Trial Design
inferred← citeshttps://doi.org/10.1007/978-981-95-9518-1_5openalex-snapshot
Master Protocol and Dose-Expansion Trials
inferred← citeshttps://doi.org/10.1007/s00109-014-1165-yopenalex-snapshot
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00270-016-1489-9openalex-snapshot
Efficacy of a Self-expanding Tract Sealant Device in the Reduction of Pneumothorax and Chest Tube Placement Rates After Percutaneous Lung Biopsy: A Matched Controlled Study Using Propensity Score Analysis
inferred← citeshttps://doi.org/10.1007/s00280-013-2124-yopenalex-snapshot
Anti-vascular endothelial growth factor therapy in the era of personalized medicine
inferred← citeshttps://doi.org/10.1007/s00280-014-2513-xopenalex-snapshot
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00280-015-2810-zopenalex-snapshot
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s00292-014-2027-7openalex-snapshot
Mutationsprofile von Tumoren jenseits von Organ- und Gewebespezifität
inferred← citeshttps://doi.org/10.1007/s00432-018-2632-6openalex-snapshot
MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
inferred← citeshttps://doi.org/10.1007/s00439-011-1010-0openalex-snapshot
Somatic variation and cancer: therapies lost in the mix
inferred← citeshttps://doi.org/10.1007/s00701-012-1536-5openalex-snapshot
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
inferred← citeshttps://doi.org/10.1007/s00761-012-2336-5openalex-snapshot
Molekulare Onkologie
inferred← citeshttps://doi.org/10.1007/s10147-018-1373-5openalex-snapshot
Clinical target sequencing for precision medicine of breast cancer
inferred← citeshttps://doi.org/10.1007/s10462-021-10058-4openalex-snapshot
Machine Learning in Drug Discovery: A Review
inferred← citeshttps://doi.org/10.1007/s10555-024-10172-zopenalex-snapshot
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance
inferred← citeshttps://doi.org/10.1007/s10585-013-9617-2openalex-snapshot
Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology
inferred← citeshttps://doi.org/10.1007/s10637-012-9812-zopenalex-snapshot
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s10637-013-0061-6openalex-snapshot
Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s10637-018-0698-2openalex-snapshot
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling
inferred← citeshttps://doi.org/10.1007/s10994-019-05784-4openalex-snapshot
Good arm identification via bandit feedback
inferred← citeshttps://doi.org/10.1007/s11523-013-0263-zopenalex-snapshot
Identification of driver mutations in lung cancer: first step in personalized cancer
inferred← citeshttps://doi.org/10.1007/s11684-013-0272-4openalex-snapshot
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
inferred← citeshttps://doi.org/10.1007/s11883-013-0321-0openalex-snapshot
Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield
inferred← citeshttps://doi.org/10.1007/s12032-016-0765-5openalex-snapshot
HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells
inferred← citeshttps://doi.org/10.1007/s12032-022-01711-1openalex-snapshot
RETRACTED ARTICLE: Artificial intelligence and machine learning in precision and genomic medicine
inferred← citeshttps://doi.org/10.1007/s12094-024-03533-1openalex-snapshot
The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12253-016-0097-yopenalex-snapshot
Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance
inferred← citeshttps://doi.org/10.1007/s12561-014-9117-1openalex-snapshot
Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials
inferred← citeshttps://doi.org/10.1007/s12561-014-9124-2openalex-snapshot
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development
inferred← citeshttps://doi.org/10.1007/s12561-016-9169-5openalex-snapshot
Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression
inferred← citeshttps://doi.org/10.1007/s12561-017-9198-8openalex-snapshot
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial with Time-to-Event Data: Comparing Group Sequential and Various Adaptive Enrichment Designs
inferred← citeshttps://doi.org/10.1007/s12561-017-9199-7openalex-snapshot
Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint
inferred← citeshttps://doi.org/10.1007/s12609-015-0192-1openalex-snapshot
Potential Therapeutic Targets in Triple Negative Breast Cancer
inferred← citeshttps://doi.org/10.1007/s13277-012-0482-4openalex-snapshot
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s13277-015-4702-6openalex-snapshot
Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s13311-016-0496-5openalex-snapshot
Toward Personalized Targeted Therapeutics: An Overview
inferred← citeshttps://doi.org/10.1007/s13665-011-0004-7openalex-snapshot
Lung cancer chemoprevention: current status and future directions
inferred← citeshttps://doi.org/10.1007/s40656-017-0135-4openalex-snapshot
Informing materials: drugs as tools for exploring cancer mechanisms and pathways
inferred← citeshttps://doi.org/10.1007/s43441-023-00570-wopenalex-snapshot
Aiding the Adoption of Master Protocols by Optimizing Patient Engagement
inferred← citeshttps://doi.org/10.1007/s43441-026-00947-7openalex-snapshot
Advancing Platform Trials in Early Oncology by Using MATS and EXNEX in Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1016/b978-0-08-102723-3.00003-2openalex-snapshot
KRAS: The Art of Understanding a Complex Gene
inferred← citeshttps://doi.org/10.1016/b978-0-12-397336-8.00002-1openalex-snapshot
Personalized Health Care (PHC) in Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-800685-6.00009-6openalex-snapshot
Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-801238-3.65288-1openalex-snapshot
New Rationales and Designs for Clinical Trials in the Era of Precision Medicine
inferred← citeshttps://doi.org/10.1016/b978-0-12-803505-4.00009-6openalex-snapshot
GTP-Competitive Inhibitors of RAS Family Members
inferred← citeshttps://doi.org/10.1016/b978-0-12-809400-6.00014-7openalex-snapshot
Vandetanib
inferred← citeshttps://doi.org/10.1016/b978-0-12-813539-6.00013-4openalex-snapshot
Tissue Is the Issue: Challenges in Oncology Clinical Trial Tissue Sample Collection for Biomarker Analyses and Companion Diagnostics
inferred← citeshttps://doi.org/10.1016/b978-0-12-822833-3.00009-7openalex-snapshot
Epithelial-mesenchymal transition and resistance to EGFR inhibitors
inferred← citeshttps://doi.org/10.1016/b978-0-12-824010-6.00063-0openalex-snapshot
Computational precision therapeutics and drug repositioning
inferred← citeshttps://doi.org/10.1016/b978-0-12-824010-6.00065-4openalex-snapshot
Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds
inferred← citeshttps://doi.org/10.1016/b978-0-323-24098-7.00013-7openalex-snapshot
Statistics and Clinical Trials
inferred← citeshttps://doi.org/10.1016/b978-0-323-24126-7.00045-4openalex-snapshot
The Molecular Biology of Thoracic Malignancies
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00017-7openalex-snapshot
Biostatistics and Bioinformatics in Clinical Trials
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00018-9openalex-snapshot
Clinical Trial Designs in Oncology
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00017-2openalex-snapshot
Classic Anatomic Pathology and Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00059-7openalex-snapshot
Clinical Trial Methodology in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00060-3openalex-snapshot
How to Promote and Organize Clinical Research in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-88423-5.00025-xopenalex-snapshot
Adaptive designs
inferred← citeshttps://doi.org/10.1016/b978-0-323-91259-4.00032-1openalex-snapshot
Translational sports medicine
inferred← citeshttps://doi.org/10.1016/b978-0-323-91790-2.00038-1openalex-snapshot
Adaptive designs
inferred← citeshttps://doi.org/10.1016/b978-0-443-13963-5.00008-xopenalex-snapshot
Precision medicine: success stories and challenges from science to implementation
inferred← citeshttps://doi.org/10.1016/b978-0-443-29808-0.00034-0openalex-snapshot
AI in the discovery and development of antibody therapeutics
inferred← citeshttps://doi.org/10.1016/b978-1-4557-2865-7.00019-9openalex-snapshot
Biostatistics and Bioinformatics in Clinical Trials
inferred← citeshttps://doi.org/10.1016/b978-1-4557-4066-6.00045-7openalex-snapshot
From Bench to Bedside with Targeted Therapies
inferred← citeshttps://doi.org/10.1016/b978-1-4557-4462-6.00002-7openalex-snapshot
Respiratory Tract and Mediastinum
inferred← citeshttps://doi.org/10.1016/j.aenj.2011.10.001openalex-snapshot
Lung cancer in the emergency department
inferred← citeshttps://doi.org/10.1016/j.ajpath.2012.10.028openalex-snapshot
Three-Dimensional mRNA Measurements Reveal Minimal Regional Heterogeneity in Esophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.artmed.2025.103272openalex-snapshot
AI-driven dynamic grouping for adaptive clinical trials: Rethinking randomization in precision medicine
inferred← citeshttps://doi.org/10.1016/j.bbacli.2014.06.003openalex-snapshot
Molecular profiling of childhood cancer: Biomarkers and novel therapies
inferred← citeshttps://doi.org/10.1016/j.bbcan.2015.01.003openalex-snapshot
Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.bbrc.2014.08.111openalex-snapshot
Rexinoid inhibits Nrf2-mediated transcription through retinoid X receptor alpha
inferred← citeshttps://doi.org/10.1016/j.bulcan.2019.01.007openalex-snapshot
La médecine de précision en oncologie : challenges, enjeux et nouveaux paradigmes
inferred← citeshttps://doi.org/10.1016/j.cancergen.2016.03.001openalex-snapshot
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.03.015openalex-snapshot
Precision oncology: A new era of cancer clinical trials
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.04.012openalex-snapshot
Induction of integrin β3 by sustained ERK activity promotes the invasiveness of TGFβ-induced mesenchymal tumor cells
inferred← citeshttps://doi.org/10.1016/j.ccell.2020.03.013openalex-snapshot
Targeting the MAPK Pathway in KRAS-Driven Tumors
inferred← citeshttps://doi.org/10.1016/j.ccell.2025.01.003openalex-snapshot
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy
inferred← citeshttps://doi.org/10.1016/j.cct.2013.05.001openalex-snapshot
A review of phase II trial designs for initial marker validation
inferred← citeshttps://doi.org/10.1016/j.cct.2013.08.007openalex-snapshot
Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research
inferred← citeshttps://doi.org/10.1016/j.cct.2013.09.009openalex-snapshot
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints
inferred← citeshttps://doi.org/10.1016/j.cct.2015.06.007openalex-snapshot
Adaptive design of confirmatory trials: Advances and challenges
inferred← citeshttps://doi.org/10.1016/j.cct.2016.11.002openalex-snapshot
A response-adaptive design of initial therapy for emergency department patients with heart failure
inferred← citeshttps://doi.org/10.1016/j.cct.2024.107547openalex-snapshot
Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials
inferred← citeshttps://doi.org/10.1016/j.cell.2013.03.002openalex-snapshot
Lessons from the Cancer Genome
inferred← citeshttps://doi.org/10.1016/j.clgc.2013.07.004openalex-snapshot
Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clgc.2014.09.004openalex-snapshot
Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clinthera.2020.05.010openalex-snapshot
The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
inferred← citeshttps://doi.org/10.1016/j.cllc.2012.09.007openalex-snapshot
KRAS Mutations in Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2013.04.002openalex-snapshot
Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non–Small-Cell Lung Cancer: Implications for Personalized Medicine
inferred← citeshttps://doi.org/10.1016/j.cmi.2018.03.011openalex-snapshot
Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases
inferred← citeshttps://doi.org/10.1016/j.conctc.2018.08.009openalex-snapshot
Master protocol trials in oncology: Review and new trial designs
inferred← citeshttps://doi.org/10.1016/j.conctc.2020.100568openalex-snapshot
Master protocols: New directions in drug discovery
showing the first 200 of 869
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.